You are here

Home » Content

Retinoid Tedavisinin Ateroskleroz Gelişimine Etkisi

The Effect of Retinoid Treatment on Atherosclerosis Development

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Aim: The aim of the present study is to determine serum changes observed in blood lipids due to isotretionin and asitretin retinoids and to reveal their potential for causing risks in terms of Atherosclerosis (AS) and Coronary artery disease (CAD). Materials and Method:The study included a total of 40 cases,, whose age ranged between 17 and 55. Results: It was seen that the increase in lipid levels was dose-dependent and returned to normal after treatment. Conclusion: In our study, increases in serum levels of LDL (low density lipoprotein), and Lipoprotein (a) (Lp(a)) were parallel. When the serum levels of these two lipids, each of which is an individual risk factor for AS and CAD, are high, the risk of AS and CAD development increases. ©2004, Fı rat Üniversitesi, Tıp Fakültesi
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bu çalışmada amacımız retinoidlerden olan isotretinoin ve asitretine bağlı olarak kan lipitlerinin serum seviyelerindeki değişimlerin belirlenmesi ve olgularda Ateroskleroz (AS) ve Koroner arter hastalığı (KAH) açısından risk oluşturma potansiyellerinin ortaya konulmasıdır. Gereç ve yöntem:Çalışmaya yaşları 17 ile 55 arasında, toplam 40 olgu alındı. Bulgular: Lipit düzeylerinin yükselmesinin doz bağımlı olduğu ve tedavi sonrasında normal düzeyine döndüğü anlaşıldı. Sonuç: Çalışmamızda Serum LDL (low density lipoprotein), ve Lipoprotein (a) (Lp(a)) değerleri yüksek bulunmuştur. Her bir değerin yüksekliği AS ve KAH açısından risk oluşturmaktadır. İkisinin birlikte yüksekliği ise bu riski daha fazla artırmaktadır.©2004, Fırat Üniversitesi, Tıp Fakültesi
FULL TEXT (PDF): 
PDF icon arastirmax-retinoid-tedavisinin-ateroskleroz-gelisimine-etkisi.pdf
  • 2
54-58
  • Turkish

REFERENCES

References: 

1. Georgala S, Schulpis KH, Potouridou I, Papadogeorgaki H. Effects of isotretinoin therapy on lipoprtein(a) serum levels. Int J
Dermatol 1997;36:863-864.
2. Marsden JR. Lipid metabolism and retinoid therapy. Pharmac
Ther 1989; 40:55-65.
3. Braunwald E. Heart disease. 5th ed., Philadelphia: W.B.Saunders Company. 2000: 1111-1147.
4. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation,
2000;102:1082-1085.
5. Marcovina SM, Koschinsky ML. Lipoprotein(a) Concentration and Apoprotein (a) size: A synergistic role in advanced atherosclerosis?. Circulation 1999; 100: 1151-1153.
6. Gotto A, Pownall H. Manual of Lipid Disorders. 2th ed.,
Philadelphia: WB -Saunders Co. 1998;105-111.
7. Murphy JG. Mayo Clınıc Cardıology Revıew. 2th ed., Philadelphia : Williams & Wilkins, 2000;134-139.
8. Rainwater DL. Lp(a) concentrations are related to plazma lipid concentrations. Atherosclerosis 1996;127:13-18.
9. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights.
Curr Opin in Lipidol 1999; 10:225-236.
10. Arı Z, Yiğitoğlu MR. Metabolism and clinical significance of lipoprotein(a). The New Journal of Medicine 1997; 14:24-26.
11. Peck GL, DiGiovanna JJ. The Retinoids. In: Freedberg Im,
Eisen Az, Wollf K, Austen KF, Goldsmith LA,Katz SI,
Fitzpatrick TB, eds. Fitzpatrick's Dermatology in Medicine, 5 th ed. New york: McGraw-Hill Company, 1999: 2810-2820.
12. Marsden J. Hyperlipidaemia due to isotretinoin and etretinate: possible mechanisms and consequences. Br J Dermatol 1986;114:401-407.
13. Staels B. Regulation of lipid and lipoprotein metabolism by
retinoids. J Am Acad Dermatol 2001; 45:S158-167.
14. O'Leary TJ, Simo IE, Kanigsberg N, Walker J, Goodall JC, Ooi TC. Changes in serum lipoproteins and high-density lipoproteins composition during isotretinoin. Clin Invest Med, 1987; 10:355¬360.15. Marcovina SM, Levine DM, Lippi G. Lipoprotein(a): structure, measurement and clinical significance. In: Rifai N, Warnick GR eds. Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington: AACC press, 1994: 235-265.
16. Sandkamp M, Funke H, Schulte H, Konler E, Assmann G. Lipoprotein (a) is an independent risk faktor for myocardial infarction at a young age. Clin chem, 1990; 36:20-23.
17. Fex GA, Aronsson A, Andersson A, Larsson K, Nilsson-Ehle P. In vivo effects of 13-cis retinoic acid treatment on the concentration of proteins and lipids in serum. Eur J Clin Chem
Clin Biochem, 1996; 34:3-7.
18. Marsden JR, Trinick TR, Laker MF, Shuster S. Effects of
isotretinoin on serum lipids and lipoproteins, liver and thyroid function. Clin Chim Acta, 1984; 143:243-251.
19. Vahlquist C, Michaelsson G, Vahlquist A, Vessby B. A sequential comparison of etretinate and isotretinoin with special regard to their effects on serum lipoproteins. Br J Dermatol,
1985; 112:69-76.
20. Kınlay S, Dobson JA, Heller RF et al. Risk of primary and recurrent acute myocardial ınfarction from lipoprotein(a) in men
and women. J Am Coll Cardiol, 1996; 28:870-875.
21. Gerber LE, Erdman JW. Changes in lipid metabolism during retinoid administration. J Am Acad Dermatol, 1982;6:664-672.
22. Grundy SM. Role of Low-Density Lipoprotein in Atherogenesis and Development of coronary heart disease. Clin Chem, 1995;
41:139-146.
23. Futterman LG, Lemberg L. Lp(a) lipoprotein an independent risk factor for coronary heart disease after menopause. Am J Crit
Care, 2001; 10:63-7.
24. Loscalzo J. Lipoprotein(a) A unique risk factor for atherothrombotic disease. Arterıosclerosis, 1990; 10(5): 672¬679.
25. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relation of lipoprotein(a) to variables of coagulation and fibrinolysis in a healty population. Clin Chem, 1991;37:1950-
1954.
26. Millionis HJ, Winder AF, Mikhailids DP. Lipoprotein (a) and
stroke. J Clin Patho 2000;53:487-496.
57
Fırat Tıp
Dergis
i 2004;9(2): 54 -58
27. Mackinnon LT, Hubinger L, Lepre F. Effects of physical activity and diet on lipoprotein (a). Med Sci Sports Exerc
1997;29:1429-1436.
28. Berglund L. Diet and drug therapy for lipoprotein(a). Curr Opin
Lipidol 1995;6:48-56.
Coşkun
29. Kronenberg F, Kronenberg M, Kiechl S et al. Role of lipoprotein(a) and Apopolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study.
Circulation 1999; 100:1154-1160.

Thank you for copying data from http://www.arastirmax.com